The reported clinical utility of taurine in ischemia disorders may reflect a down-regulation of neutrophil activation and adhesion

Medical Hypotheses

Volumn 53, Issue 4, 1999, Pages 290-299

  McCarty, M F ^a  

^a Nutrition 21   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; GINKGOLIDE; HYPOCHLOROUS ACID; LEUKOTRIENE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE; PROTEIN; TAURINE; THIOL DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR;

ANGINA PECTORIS; BRAIN ATHEROSCLEROSIS; CLINICAL TRIAL; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

ANGINA;

EID: 0032758931     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0760     Document Type: Article

References (166)

1. Hayes K. C., Pronczuk A., Addesa A. E., Stephan Z. F. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr. 49:1989;1121-1126.
2. Franconi F., Miceli M., Bennardini F. Taurine potentiates the antiaggregatory action of aspirin and indomethacin. Lombardini J. B. Taurine. 1992;181-186 Plenum Press, New York.
3. Franconi F., Bennardini F., Mattana A. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr. 61:1995;1115-1119.
4. Azuma J., Sawamura A., Awata N. Double-blind randomized cross-over trial of taurine in congestive heart failure. Curr Ther Res. 34:1983;543-557.
5. Azuma J., Sawamura A., Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 56:1992;95-99.
6. Huxtable R., Michalk D. V. Taurine in Health and Disease. 1994;425-433 Plenum Press, New York.
7. Takihara K., Azuma J., Awata N. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J. 112:1986;1278-1284.
8. Yamaguchi A., Kanda S., Amano H. Jpn J Geriatr. 4:1967;96.
9. Kohashi N., Okabayashi T., Hama J., Katori R. Decreased urinary taurine in essential hypertension. Kuriyama K., Huxtable R. J., Iwata H. Sulfur Amino Acids: Biochemical and Clinical Aspects. 1983;73-87 Alan R. Liss, Inc. New York.
10. Fujita T., Ando K., Noda H. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 75:1983;525-532.
11. Nara Y., Yamori Y., Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharm. 27:1978;2687-2692.
12. Inoue A., Takahashi H., Lee L-C. Retardation of the development of hypertension in DOCA salt rats by taurine supplement. Cardiovasc Res. 22:1988;351-358.
13. Nakagawa, M. Takeda, K. Yoshitomi, T. Antihypertensive effect of taurine on salt-induced hypertension, Taurine in Health and Disease, op. cit. 197, 206.
14. Milei J., Ferreira R., Llesuy S. Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization. Am Heart J. 123:1992;339-345.
15. Franconi F., Stendardi I., Failli P. The protective effects of taurine on hypoxia (performed in the absence of glucose) and on reoxygenation (in the presence of glucose) in guinea-pig heart. Biochem Pharm. 34:1985;2611-2615.
16. Raschke P., Massoudy P., Becker B. F. Taurine protects the heart from neutrophil-induced reperfusion injury. Free Rad Biol Med. 19:1995;461-471.
17. Becattini U. Prospective di un nuovo farmaco nella terapia delle vasculopatie: la taurina. Sett Med. 55:1967;1355.
18. Sicuteri F., Franchi G., Fanciullacci M. Sull'azione antianginosa di un aminoacido solforato non coronariodilatatore. Clin Ter. 49:1969;205-219.
19. Gagliarducci U. Sul trattamento delle cardiopatie ischemiche acute con taurina. Clin Ter. 68:1973;261-270.
20. Montanini R., Zibetti A., Gasco P. Osservazioni preliminari sull'impiego della taurina nel trattamento delle vasculopatie cerebrali. Clin Ter. 59:1971;321-329.
21. Montanini R., Gasco P. La taurina nel trattamento delle arteriopatie cerebrali diffuse. Clin Ter. 71:1974;427-736.
22. Cherchi A., Lai C., Angelino F. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 23:1985;569-572.
23. Brevetti G., Chiariello M., Ferulano G. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 77:1988;767-773.
24. 10on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 56:1985;247-251.
25. 10a new drug for cardiovascular disease. J Clin Pharmacol. 30:1990;596-608.
26. Worthen G. S., Schwab B. III, Elson E. L., Downey G. P. Mechanics of stimulated neutrophils: cell stiffening induces retention in capillaries. Science. 245:1989;183-186.
27. Engler R. L., Schmid-Schönbein G. W., Pavelec R. S. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 111:1983;98-111.
28. Schmid-Schönbein G. W. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Fed Proc. 46:1987;2397-2401.
29. Ernst E., Hammerschmidt D. E., Bagge U. Leukocytes and the risk of ischemic diseases. J Am Med Assoc. 257:1987;2318-2324.
30. Matrai A., Ernst E. Pentoxifylline improves white cell rheology in claudicants. Clin Hemorheol. 5:1985;483-491.
31. Hammerschmidt D. E., Kotasek D., McCarthy T. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med. 112:1988;254-263.
32. Braquet, P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from ginkgo biloba L, Zor, U.Naor, Z.Kohen, F. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Raven Press, New York, 1986, 179, 198.
33. Vercellotti G. M., Wickham N. W. R., Gustafson K. S. Thrombin-treated endothelium primes neutrophil functions: inhibition by platelet-activating factor receptor antagonists. J Leukocyte Biol. 45:1989;483-490.
34. Braquet P., Paubert-Braquet M. Is there a case for PAF antagonists in the treatment of ischemic states. Trends Pharm Sci. 10:1989;23-30.
35. Kleijnen J., Knipschild P. Lancet. 340:1992;1136-1139.
36. Ryan U. S. Structural basis for endothelial cell function: role of calcium, polyphosphoinositide turnover and G-proteins. Catravas J. D., Gillis C. N., Ryan U. S. Vascular Endothelium. Receptors and Transduction Mechanisms. 1988;3-20 Plenum Press, New York.
37. McIntyre T. M., Zimmerman G. A., Satoh K., Prescott S. M. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest. 76:1985;271-280.
38. Whatley R. E., Nelson P., Zimmerman G. A. The regulation of platelet-activating factor production in endothelial cells. J Biol Chem. 264:1989;6325-6333.
39. Whatley R. E., Fennell D. F., Kurrus J. A. Synthesis of platelet-activating factor by endothelial cells. The role of G proteins. J Biol Chem. 265:1990;15,550-15,559.
40. Hayashi M., Imai Y., Oh-ishi S. Phorbol ester stimulates PAF synthesis via the activation of protein kinase C in rat leukocytes. Lipids. 26:1991;1054-1059.
41. Murohara T., Parkinson S. J., Waldman S. A., Lefer A. M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler Thromb Vasc Biol. 15:1995;2068-2075.
42. Murohara T., Scalia R., Lefer A. M. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res. 78:1996;780-789.
43. Kubes P., Ibbotson G., Russell J. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol. 259:1990;G300-G305.
44. Zimmerman G. A., Prescott S. M., McIntyre T. M. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today. 13:1992;93-100.
45. Shaw J. O., Pinckard R. N., Ferrigni K. S. Activation of human neutrophils with 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol. 127:1981;1250-1255.
46. Gay J. C., Beckman J. K., Zaboy K. A., Lukens J. N. Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. Blood. 67:1986;931-936.
47. Vercellotti G. M., Yin H. Q., Gustafson K. S. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. Blood. 71:1988;1100-1107.
48. Heller R., Bussolino F., Ghigo D. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharm. 44:1992;223-229.
49. Heller R., Bussolino F., Ghigo D. Activation of endothelial guanylate cyclase inhibits cellular reactivity. Agents Actions. 45:1995;177-181.
50. Arndt H., Russell J. B., Kurose I. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology. 105:1993;675-680.
51. Zimmerman G. A., McIntyre T. M., Prescott S. M. Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for speci?c agonists and modulation by prostacyclin. Circulation. 72:1985;718-727.
52. Heller R., Bussolino F., Ghigo D. Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochim Biophys Acta. 1093:1991;55-64.
53. Gauthier T. W., Davenpeck K. L., Lefer A. M. Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol. 267:1994;G562-G568.
54. Davenpeck K. L., Gauthier T. W., Lefer A. M. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology. 107:1994;1050-1058.
55. Clancy R. M., Leszczynska-Piziak J., Abramson S. B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 90:1992;1116-1121.
56. Simpson P. J., Mitsos S. E., Ventura A. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J. 113:1987;129-137.
57. Simpson P. J., Mickelson J., Fantone J. C. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res. 60:1987;666-673.
58. Kubes P., Suzuki M., Granger D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci. 88:1991;4651-4655.
59. Niu X-F., Smith C. W., Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res. 74:1994;1133-1140.
60. Ma X-L., Weyrich A. S., Lefer D. J., Lefer A. M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res. 72:1993;403-412.
61. Wallace J. L., Granger D. N. Pathogenesis of NSAID gastropathy: are neutrophils the culprits. Trends Pharm Sci. 13:1992;129-131.
62. Naito Y, Yoshikawa T., Kaneko T. Role of oxygen radicals in indomethacin-induced gastric mucosal microvascular injury in rats. J Clin Gastroenterol. 17:1993;S99-S103.
63. Kanagy N. L., Charpie J. R., Webb R. C. Nitric oxide regulation of ADP-ribosylation of G proteins in hypertension. Med Hypoth. 44:1995;159-164.
64. Lang D., Lewis M. J. Inhibition of inositol 1,4,5-trisphosphate formation by cyclic GMP in cultured aortic endothelial cells of the pig. Br J Pharmacol. 102:1991;207-281.
65. Iresponses are negatively modulated via a cGMP-dependent protein kinase I pathway. J Biol Chem. 270:1995;22,277-22,282.
66. Deana R., Ruzzene M., Doni M. G. Cyclic GMP and nitroprusside inhibit the activation of human platelets by ?uoroaluminate. Biochim Biophys Acta. 1014:1989;203-206.
67. Galas M-C., Harden T. K. Cyclic AMP-induced desensitization of G-protein-regulated phospholipase C in turkey erythrocyte membranes. Eur J Pharmacol. 314:1996;157-164.
68. De Caterina R., Libby P., Peng H-B. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proin?ammatory cytokines. J Clin Invest. 96:1995;60-68.
69. Zeiher A. M., Fisslthaler B., Schray-Utz B., Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 76:1995;980-986.
70. Peng H-B., Rajavashisth T. B., Libby P., Liao J. K. Nitric oxide inhibits macrophagecolony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem. 270:1995;17,050-17,055.
71. Takahashi M., Ikeda U., Masuyama J-I. Nitric oxide attenuates adhesion molecule expression in human endothelial cells. Cytokine. 8:1996;817-821.
72. Khan B. V., Harrison D. G., Olbrych M. T. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci. 93:1996;9114-9119.
73. Tsao P. S., Buitrago R., Chan J. R., Cooke J. P. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation. 94:1996;1682-1689.
74. Fleming I., Bauersachs J., Busse R. Paracrine functions of the coronary vascular endothelium. Mol Cell Biochem. 157:1996;137-145.
75. Kourembanas S., McQuillan L. P., Leung G. K., Faller D. V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 92:1993;99-104.
76. Khachigian L. M., Resnick N., Gimbrone M. A. Jr., Collins T. Nuclear factor-κB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest. 96:1995;1169-1175.
77. Collins T. Endothelial nuclear factor-?B and the initiation of the atherosclerotic lesion. Lab Invest. 68:1993;499-508.
78. Marui N., Offermann M. K., Swerlick R. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an anti-oxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 92:1993;1866-1874.
79. Weber C., Negrescu E., Erl W. Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. J Immunol. 155:1995;445-451.
80. Ferran C., Millan M. T., Csizmadia V. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Comm. 214:1995;212-223.
81. Andalibi A., Liao F., Imes S. Oxidized lipoproteins in?uence gene expression by causing oxidative stress and activating the transcription factor NF-kappa B. Biochem Soc Trans. 21:1993;651-665.
82. Maziere C., Auclair M., Djavaheri-Mergny M. Oxidized low density lipoprotein induces activation of the transcription factor NF-kappa B in fibroblasts, endothelial and smooth muscle cells. Biochem Mol Biol Int. 39:1996;1201-1207.
83. Takahara N., Kashiwagi A., Nishio Y. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNAexpression in cultured human endothelial cells. Diabetologia. 40:1997;662-670.
84. Zhu Y., Liao H-L. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta. 1345:1997;93-98.
85. Bierhaus A., Chevion S., Chevion M. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes. 46:1997;1481-1490.
86. Peng H-B., Libby P., Liao J. K. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem. 270:1995;14,214-14,219.
87. Lindström P, Lerner R., Palmblad J., Patarroyo M. Rapid adhesive responses of endothelial cells and of neutrophils induced by leukotriene B4 are mediated by leukocytic adhesion protein CD18. Scand J Immunol. 31:1990;737-744.
88. Test S. T., Weiss S. J. The generation of utilization of chlorinated oxidants by human neutrophils. Adv Free Rad Biol Med. 2:1986;91-116.
89. Del Maestro R. F., Planker M., Arfors K-E. Evidence for the participation of superoxide anion radical in altering the adhesive interaction between granulocytes and endothelium, in vivo. Int J Microcirc Clin Exp. 1:1982;105-120.
90. Gaboury J. P., Anderson D. C., Kubes P. Molecular mechanisms invovled in superoxide-induced leukocyte-endothelial cell interactions in vivo. Am J Physiol. 266:1994;H637-H642.
91. Lewis M. S., Whatley R. E., Cain P. Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest. 82:1988;2045-2055.
92. Gasic A. C., McGuire G., Krater S. Hydrogen peroxide pretreatment of perfused canine vessels induces ICAM-1 and CD18-dependent neutrophil adherence. Circulation. 84:1991;2154-2166.
93. Siflinger-Birnboim A., Goligorsky M. S., Del Vecchio P. J., Malik A. B. Activation of protein kinase C pathway contributes to hydrogen peroxide-induced increase in endothelial permeability. Lab Invest. 67:1992;24-30.
94. Fliss H. Oxidation of proteins in rat heart and lungs by polymorphonuclear leukocyte oxidants. Mol Cell Biochem. 84:1988;177-188.
95. 2+ATPase activity by hypochlorous acid: reversal by dithiothreitol. Can J Physiol Pharmacol. 69:1991;1677-1685.
96. McLoughlin D. M., Stapleton P. P., Bloomfield F. J. Influence of taurine and a substituted taurine on the respiratory burst pathway in the inflammatory response. Biochem Soc Trans. 19:1991;73-78.
97. Marcinkiewicz J., Grabowska A., Bereta J., Stelmaszynska T. Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage in?ammatory mediators. J Leukoc Biol. 58:1995;667-674.
98. Kim C., Park E., Quinn M. R., Schuller-Levis G. The production of superoxide anion and nitric oxide by cultured murine leukocytes and the accumulation of TNF-alpha in the conditioned media is inhibited by taurine chloramine. Immunopharmacol. 34:1996;89-95.
99. Masuda M., Horisaka K., Koeda T. Influences of taurine on functions of rat neutrophils. Jpn J Pharmacol. 34:1984;116-118.
100. Suzuki M., Asako H., Kubes P. Neutrophil-derived oxidants promote leukocyte adherence in postcapillary venules. Microvasc Res. 42:1991;125-138.
101. Patel J. M., Block E. R. Sulfydrul-disulflde modulation and the role of disulflde oxidoreductases in regulation of the catalytic activity of nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol. 13:1995;352-359.
102. Patel J. M., Zhang J., Block E. R. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am J Respir Cell Mol Biol. 15:1996;410-419.
103. Raschke P., Becker B. F., Leipert B. Postischemic dysfunction of the heart induced by small numbers of neutrophils via formation of hypochlorous acid. Basic Res Cardiol. 88:1993;321-339.
104. Ayajiki K., Kindermann M., Hecker M. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res. 78:1996;750-758.
105. Fleming I., Hecker M., Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cells. Circ Res. 74:1994;1220-1226.
106. +antiport activity in bovine pulmonary artery endothelial cells. Am J Physiol. 267:1994;L649-L659.
107. Okabe E., Takahashi S-S., Norisue M. The effect of hypochlorous acid and hydrogen peroxide on coronary ?ow and arrhythmogenesis in myocardial ischemia and reperfusion. Eur J Pharmacol. 248:1993;33-39.
108. Tatsumi T., Fliss H. Hypochlorous acid and chloramines increase endothelial permeability: possible involvement of cellular zinc. Am J Physiol. 267:1994;H1597-H1607.
109. Kubes P., Granger D. N. Nitric oxide modulates microvascular permeability. Am J Physiol. 262:1992;H611-H615.
110. Schreck R., Albermann K., Baeuerle P. A. Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Rad Res Comms. 17:1992;221-237.
111. Suzuki Y. J., Aggarwal B. B., Packer L. α-Lipoic acid is a potent inhibitor of NF-?B activation in human T cells. Biochem Biophys Res Com. 189:1992;1709-1715.
112. Meyer M., Pahl H. L., Baeuerle P. A. Regulation of the transcription factors NF-?B and AP-1 by redox changes. Chem-Biol Interact. 91:1994;91-100.
113. Schenk H., Klein M., Erdbrügger W. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc Natal Acad Sci. 91:1994;1672-1676.
114. Anderson M. T., Staal F. J. T., Gitler C. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc Natl Acad Sci. 91:1994;11,527-11,531.
115. Ferran C., Millan M. T., Csizmadia V. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Comm. 214:1995;212-223.
116. Schoonbroodt S., Legrand-Poels S., Best-Belpomme M., Piette J. Activation of NF-κB transcription factor in a T-lymphocytic cell line by hypochlorous acid. Biochem J. 321:1997;777-785.
117. Son M., Kim H. K., Kim W. B. Protective effect of taurine on indomethacin-induced gastric mucosal injury. Huxtable R. J., Azuma J., Kuriyama K. Taurine 2. Basic and Clinical Aspect. 1996;147-155 Plenum Press, New York.
118. Barry M. C., Kelly C. J., Abdih H. Differential effects of lower limb revascularisation on organ injury and the role of the amino acid taurine. Eur J Vasc Endovasc Surg. 13:1997;193-201.
119. Petty M. A., Kintz J., DiFrancesco G. F. The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur J Pharmacol. 180:1990;119-127.
120. Wang Q, Giri S. N., Hyde D. M., Nakashima J. M. Effect of taurine on bleomycin-induced lung fibrosis in hamsters. Proc Soc Exp Biol Med. 190:1989;330-338.
121. Wang Q., Hyde D. M., Giri S. N. Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin. Lab Invest. 67:1992;234-242.
122. Trachtman H., Del Pizzo R., Futterweit S. Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy. Am J Physiol. 262:1992;F117-F123.
123. Wascher T. C., Posch K., Wallner S. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase. Biochem Biophys Res Comm. 234:1997;35-38.
124. Sato H., Zhao Z. Q., Vinten-Johansen J. L-arginine inhibits neutrophil adherence and coronary artery dysfunction. Cardiovasc Res. 31:1996;63-72.
125. Tsao P. S., McEvoy L. M., Drexler H. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 89:1994;2176-2182.
126. Nakanishi K., Vinten-Johnsen J., Lefer D. J. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 263:1992;H1650-H1658.
127. Weyrich A. S., Ma X. L., Lefer A. M. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 86:1992;279-288.
128. Haramatsu T., Forbess J. M., Miura T. Additive effects of L-arginine infusion and leukocyte depletion on recovery after hypothermic ischemia in neonatal lamb hearts. J Thorac Cardiovasc Surg. 110:1995;172-179.
129. Amrani M., Chester A. H., Jayakumar J. L-arginine reverses low coronary reflow and enhances postischaemic recovery of cardiac mechanical function. Cardiovasc Res. 30:1995;200-204.
130. Engelman D. T., Watanabe M., Maulik N. L-arginine reduces endothelial in?ammation and myocardial stunning during ischemia/reperfusion. Ann Thorac Surg. 60:1995;1275-1281.
131. Jonas E., Dwenger A., Hager A. In vitro effect of ascorbic acid on neutrophil-endothelial cell interaction. J Biolumin Chemilumin. 8:1993;15-20.
132. Moncada S., Gryglewski R. J., Bunting S. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 12:1976;715-737.
133. Pinsky M. J. Treatment of intermittent claudication with alpha-tocopherol. J Am Podiatry Assoc. 70:1980;454-458.
134. Doni M. G., Avventi G. L., Bonadiman L., Bonaccorso G. Glutathione peroxidase selenium, and prostaglandin synthesis in platelets. Am J Physiol. 240:1981;H800-H803.
135. Schiavon R., Freeman G. E., Guidi G. C. Selenium enhances prostacyclin production by cultured endothelial cells: possible explanation for increased bleeding times in volunteers taking selenium as a dietary supplement. Thromb Res. 34:1984;389-396.
136. Hampel G., Watanabe K., Weksler B. B., Jaffe E. A. Selenium deficiency inhibits prostacyclin release and enhances production of platelet activating factor by human endothelial cells. Biochim Biophys Acta. 1006:1989;151-158.
137. Gladyshev V. N., Jeang K-T., Stadtman T. C. Selenocysteine, identi?ed as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci. 93:1996;6146-6151.
138. Makropoulos V., Brüning T., Schulze-Osthoff K. Selenium-mediated inhibition of transcription factor NF-κB and HIV-1 LTF promoter activity. Arch Toxicol. 70:1996;277-283.
139. Packer L., Witt E. H., Tritschler H. J. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. 19:1995;227-250.
140. Serbinova E., Khwaja S., Reznick A. Z., Packer L. Thiotic acid protects against ischemia-reperfusion injury in the isolated perfused Langendorff heart. Free Rad Res Comms. 17:1992;49-58.
141. Sperling R. I., Weinblatt M., Robin J-L. Effects of dietary supplementation with marine ?sh oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arth Rheum. 30:1987;988-997.
142. Arm J. P., Lee T. H. The use of fish oil in bronchial asthma. Allergy Proc. 10:1989;185-187.
143. Sperling R. I. Effects of dietary fish oil on leukocyte leukotriene and PAF generation and on neutrophil chemotaxis. Simopoulos A. P., Kifer R. R., Martin R. E., Barlow S. M. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. 1991;391-400 Karger, Basel.
144. Shikano M., Masuzawa Y., Yazawa K. Effect of docosahexaenoic acid on the generation of platelet-activating factor by eosinophilic leukemia cells, Eol-1. J Immunol. 150:1993;3525-3533.
145. Sperling R. I., Benincaso A. I., Knoell C. T. Dietary ω-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest. 91:1993;651-660.
146. 2during the hydrolysis of diacyl-and alkenylacylglycerophosphoethanolamine. Biochim Biophys Acta. 1212:1994;211-216.
147. Triggiani M., Connell T. R., Chilton F. H. Evidence that increasing the cellular content of eicosapentaenoic acid does not reduce the biosynthesis of platelet-activating factor. J Immunol. 145:1990;2241-2248.
148. De Caterina R., Cybulsky M. I., Clinton S. K. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. 14:1994;1829-1836.
149. De Caterina R., Cybulsky M. I., Clinton S. K. Omega-3 fatty acids and endothelial leukocyte adhesion molecules. Prost Leuk Essent Fatty Acids. 52:1995;191-195.
150. De Caterina R., Libby P. Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids. 31:1996;S57-S63.
151. Collie-Duguid E S R, Wahle K. W. J. Inhibitory effect of ?sh oil n-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Comm. 220:1996;969-974.
152. Weber C., Erl W., Pietsch A. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-α Arterioscler Thromb Vasc Biol. 15:1995;622-628.
153. Lehr H-A., Hübner C., Finckh B. Dietary fish oil reduces leukocyte/endothelium interaction following systemic administration of oxidatively modified low density lipoprotein. Circulation. 84:1991;1725-1731.
154. Lee T. H., Hoover R. L., Williams J. D. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 312:1985;1217-1224.
155. Leaf A. Cardiovascular effects of fish oils. Circulation. 82:1990;624-628.
156. Saynor R., Verel D., Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis. 50:1984;3-10.
157. Kristensen S. D., Schmidt E. B., Andersen H. R., Dyerberg J. Fish oil in angina pectoris. Atherosclerosis. 64:1987;13-19.
158. Mehta J. L., Lopez L. M., Lawson D. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Am J Med. 84:1988;45-52.
159. Solomon S. A., Cartwright I., Pockley G. A placebo-controlled, double-blind study of eicosapentaenoic acid-rich ?sh oil in patients with stable angina pectoris. Curr Med Res Opin. 12:1990;1-11.
160. Aucamp A. K., Schoeman S. H., Coetzee J. H. J. Pilot trial to determine the ef?cacy of a low dose of ?sh oil in the treatment of angina pectoris in the geriatric patient. Prost Leuk Essent Fatty Acids. 49:1993;687-689.
161. Salachas A., Papadopoulos C., Sakadamis G. Effects of a low-dose ?sh oil concentrate on angina, exercise tolerance time, serum triglycerides, and platelet function. Angiology. 45:1994;1023-1031.
162. Gans R. O. B., Bilo H. J. G., Weersink E. G. L. Fish oil supplementation in patients with stable claudication. Am J Surg. 160:1990;490-495.
163. Saynor R., Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subject receiving fish oil supplements and followed for seven years. Lipids. 27:1992;533-538.
164. Setnikar I., Cereda R., Pacini M. A., Revel L. Antireactive properties of glucosamine sulfate. Arzneim-Forsch. 41:1991;157-161.
165. Setnikar I., Pacini M. A., Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneim-Forsch. 41:1991;542-545.
166. McCarty M. F. Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier - implications for use of glucosamine in inflammatory disorders. Med Hypoth. 1997.